Crémieux
Crémieux
ADA-0,71 %
Eli Lilly just showed that you can lose tons of fat while barely losing any muscle using their activin type-II receptor inhibitor, bimagrumab. We are approaching a golden era of weight loss, where everyone can easily be muscular and skinny. Prepare for hordes of hot Americans.
Gallery 1
The semaglutide-only weight loss results also speak against the lie that GLP-1RAs cause excess lean mass loss, as the proportion lost was comparable to typical non-GLP-1RA weight loss. To learn more, check out the update I just made on this article:
Reporting on this result from the ADA 2025 conference:
Egan Peltan
Egan Peltan
Can less weight loss be better weight loss? This morning at ADA, Eli Lilly released data on the Believe Phase 2b study of Bimagrumab in combination with a GLP-1 (Semaglutide) The goal: lose only fat Approach: anorectic + anabolic
@subtlechemism Nope.
Crémieux
Crémieux
A new study of NAION risk with GLP-1RAs just came out. With semaglutide, there was not only no apparent risk, but if anything, there was reduced risk.
Gallery 1
@cmoncanes There's never been good evidence for them. It just doesn't gomd up on closer inspection.
Crémieux
Crémieux
A new study of NAION risk with GLP-1RAs just came out. With semaglutide, there was not only no apparent risk, but if anything, there was reduced risk.
Gallery 1
@AnnieTyzak Eye issues? Never supported with strong evidence.
Crémieux
Crémieux
A new study of NAION risk with GLP-1RAs just came out. With semaglutide, there was not only no apparent risk, but if anything, there was reduced risk.
Gallery 1
@elonmusk And it seems like consumers will have options, too. Multiple other companies are close to their own versions of this product: We live in amazing times!
Crémieux
Crémieux
More companies are jumping in to improve GLP-1-driven weight loss. Scholar Rock is now reporting their own results from using combination tirzepatide and a myostatin inhibitor. At 24 weeks, their results are comparable to semaglutide at 26 weeks with Regeneron's inhibitor:
Gallery 1
@AZchilly Then I'd say you didn't read the article. Here's a helpful thread with human rather than non-human primate results.
Crémieux
Crémieux
More companies are jumping in to improve GLP-1-driven weight loss. Scholar Rock is now reporting their own results from using combination tirzepatide and a myostatin inhibitor. At 24 weeks, their results are comparable to semaglutide at 26 weeks with Regeneron's inhibitor:
Gallery 1
Zdrojem jetwitter
8,12 tis.
0
Obsah na této stránce poskytují třetí strany. Není-li uvedeno jinak, společnost OKX není autorem těchto informací a nenárokuje si u těchto materiálů žádná autorská práva. Obsah je poskytován pouze pro informativní účely a nevyjadřuje názory společnosti OKX. Nejedná se o doporučení jakéhokoli druhu a nemělo by být považováno za investiční poradenství ani nabádání k nákupu nebo prodeji digitálních aktiv. Tam, kde se k poskytování souhrnů a dalších informací používá generativní AI, může být vygenerovaný obsah nepřesný nebo nekonzistentní. Další podrobnosti a informace naleznete v připojeném článku. Společnost OKX neodpovídá za obsah, jehož hostitelem jsou externí weby. Držená digitální aktiva, včetně stablecoinů a tokenů NFT, zahrnují vysokou míru rizika a mohou značně kolísat. Měli byste pečlivě zvážit, zde je pro vás obchodování s digitálními aktivy nebo jejich držení vhodné z hlediska vaší finanční situace.